The role of viruses in human cancer development and antiviral approaches for intervention

Current Opinion in Investigational Drugs

Volumn 3, Issue 11, 2002, Pages 1574-1579

  Kadow, John F ^a   Regueiro Ren, Alicia ^a   Weinheimer, Steven P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cancer; DNA virus; Epstein Barr virus; Hepatitis; Herpes; Leukemia; Papillomavirus; RNA virus

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CIDOFOVIR; ENTECAVIR; FOSCARNET; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; INTERFERON; NUCLEOSIDE DERIVATIVE; RIBAVIRIN; RITUXIMAB; VIRUS VACCINE; ZIDOVUDINE;

AIDS RELATED COMPLEX; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DNA VIRUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EPSTEIN BARR VIRUS; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN T CELL LEUKEMIA VIRUS; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INHIBITION KINETICS; KAPOSI SARCOMA; LIVER CANCER; LIVER CELL CARCINOMA; LYMPHOMA; MOLECULAR MECHANICS; NONHUMAN; PAPILLOMA VIRUS; POLYOMA VIRUS; PRIMARY EFFUSION LYMPHOMA; REVIEW; RNA VIRUS; SIDE EFFECT; T CELL LEUKEMIA; UTERINE CERVIX CANCER; VACCINATION; VERRUCA VULGARIS; VIRAL PHENOMENA AND FUNCTIONS; VIRUS CARCINOGENESIS; VIRUS CELL TRANSFORMATION; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA VIRUSES; HUMANS; NEOPLASMS; RNA VIRUSES;

EID: 0036881431     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Hoppe-Seyler F, Butz K: In: The Molecular Basis of Human Cancer. Coleman WB, Tsongalis GJ (Eds), Humana Press Inc, Totowa, NJ, USA (2002):233-247. A comprehensive review of the mechanisms of viral carcinogenesis.
2. Zur Hausen H: Oncogenic DNA viruses. Oncogene (2001) 20:7820-7823. An informative review with perspectives from someone experienced in the field.
3. Hermine O, Lefrere F, Bronowicki J-P, Mariette X, Jondeau K, Eclache-Saundreau V, Delmas B, Valensi F, Cacoub P, Brechot C, Varet B et al: Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Eng J Med (2002) 347:89-94.
4. Klein G: Perspectives in studies of human tumor viruses. Front Biosci (2002) 7:D268-D274. An interesting general review which includes historical perspectives on the evolution and significant milestones in the field.
5. Abdulkarim B, Bourhis J: Antiviral approaches for cancers related to Epstein-Barr virus and human papillomavirus. Lancet Oncol (2001) 2:622-630. An interesting review which addresses approaches for therapeutic intervention.
6. Pagano JS: Viruses and lymphomas. N Engl J Med (2002) 347:78-79. An interesting and informative perspective on viruses and lymphomas.
7. Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D, Rowe JM: The effect of antiviral therapy on t(14,18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood (2001) 97:1555-1559.
8. Bartenschlager R: In vitro models for hepatitis C. Virus Res (2002) 82:25-32.
9. Pietschmann T, Bartenschlager R: The hepatitis C virus replicon system and its application to molecular studies. Curr Opin Drug Discovery Dev (2001) 4:657-664.
10. Ideo G, Bellobuono A: New therapies for the treatment of chronic hepatitis C. Curr Pharm Des (2002) 8:959-966.
11. Myles DC: Recent advances in the discovery of small molecule therapies for HCV. Curr Opin Drug Discovery Dev (2001) 4:411-416.
12. Dymock BW: Emerging therapies for hepatitis C virus infection. Emerging Drugs (2001) 6:13-42.
13. Neuveut C, Jeang KT: Cell cycle dysregulation by HTLV-1: Role of the Tax oncoprotein. Front Biosci (2002) 7:D157-D163.
14. Bazarbachi A, Hermine O: Treatment of adult T-cell leukemia/lymphoma: Current strategy and future perspectives. Virus Res (2001) 78:79-92.
15. Kenney JL, Guinness ME, Reiss M, Lacy J: Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) sensitizes EBV-immortalized B cells to transforming growth factor-β and chemotherapeutic agents. Int J Cancer (2001) 91:89-98.
16. Kenney JL, Guinness ME, Curiel T, Lacy J: Antisence to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and Bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood (1998) 92:1721-1727.
17. Morgan MB, Goldstein NB, Scadden D, Lacy J, Curiel DT, Curiel TJ: Treatment of EBV transformed tumors with antisense oligodeoxynucleotides against EBNA-1 enhances tumor chemosensitivity. Tumor Targeting 2000, 4:278-286.
18. Hopwood PA, Brooks L, Parratt R, Hunt BJ, Maria B, Alero TJ, Magdi Y, Crawford DH: Persistent Epstein-Barr virus infection: Unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients. Transplantation (2002) 74:194-202.
19. Rowe DT, Webber S, Schauer EM, Reyes J, Green M: Epstein-Barr virus load monitoring: Its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis (2001) 3:79-87.
20. Niedobitek G, Meru N, Delecluse HJ: Epstein-Barr virus infection and human malignancies. Int J Exp Pathol (2001) 82:149-170.
21. Green M, Reyes J, Webber S, Rowe D: The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl Infect Dis (2001) 3:97-103.
22. Oertel SH, Riess H: Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations. Recent Results Cancer Res (2002) 159:89-95.
23. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW et al: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med (1994) 330:1185-1191.
24. Rooney CM, Aguilar LK, Huls MH, Brenner MK, Heslop HE: Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol (2001) 258:221-229.
25. Heslop HE, Perez M, Benaim E, Rochester R, Brenner MK, Rooney CM: Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. J Clin Apheresis (1999) 14:154-156.
26. Hanel M, Fiedler F, Thorns C: Anti-CD20 monoclonal antibody (rituximab) and cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie (2001) 24:491-494.
27. Kedes DH, Ganem D: Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest (1997) 99:2082-2086.
28. De Clercq E: Guanosine analogues as anti-herpesvirus agents. Nucleosides Nucleotides Nucleic Acids (2000) 19:1531-1541.
29. Murono S, Raab-Traub N, Pagano JS: Prevention and inhibition of nasopharyngeal carcinoma growth by antiviral phosphonated nucleoside analogs. Cancer Res (2001) 61:7875-7877.
30. Neyts J, Sadler R, De Clercq E, Raab-Traub N, Pagano JS: The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice. Cancer Res (1998) 58:384-388.
31. Lee RK, Cai JP, Deyev V, Gill PS, Cabral L, Wood C, Agarwal RP, Xia W, Boise LH, Podack E, Harrington WJ Jr: Azidothymidine and interferon-α induce apoptosis in herpesvirus-associated lymphomas. Cancer Res (1999) 59:5514-5520.
32. Toomey NL, Deyev VV, Wood C, Boise LH, Scott D, Liu LH, Cabral L, Podack ER, Barber GN, Harrington WJ Jr: Induction of a TRAIL-mediated suicide program by interferon α in primary effusion lymphoma. Oncogene (2001) 20:7029-7040.
33. Boshoff C, Weiss R: AIDS-related malignancies. Nat Rev Cancer (2002) 2:373-382.
34. Weiss RA: Viruses, cancer and AIDS. FEMS Immunol Med Microbiol (1999) 26:227-232.
35. Mazzi R, Parisi SG, Sarmati L, Uccella I, Nicastri E, Carolo G, Gatti F, Concia F, Andreoni M: Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS. AIDS (2001) 15:2061-2062.
36. Hammound Z, Parenti DM, Simon GL: Abatement of cutaneous Kaposi's sarcoma associated with cidofovir treatment. Clin Infect Dis (1998) 26:1233.
37. Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM: Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS (2001) 15:280-282.
38. Zur Hausen H: Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer (2002) 2:342-350. A thorough review of papillomaviruses from an expert in the field.
39. Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, Zacny VL: Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene (2001) 20:7888-7898.
40. Dell G, Gaston K: Human papillomaviruses and their role in cervical cancer. Cell Mol Life Sci (2001) 58:1923-1942.
41. Ferenczy A, Franco E: Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol (2002) 3:11-16.
42. Leigh IM, Breuer JA, Buchanan JAG, Harwood CA, Jackson S, McGregor JM, Proby CM, Storey A: Human papilloma virsuses and cancers of the skin and oral mucosa. In: Infectious Causes of Cancer. Goedert JJ (Ed), Humama Press Inc, Totowa, NJ, USA (2002):289-309.
43. Wilson FX: Emerging therapies for human papillomavirus infection. Exp Opin Emerging Drugs (2001) 6:199-207.
44. Mantovani F, Banks L: The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene (2001) 20:7874-7887.
45. Goodwin EC, DiMaio D: Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci USA (2000) 97:12513-12518.
46. Hu G, Liu W, Hanania EG, Fu S, Wang T, Deisseroth AB: Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells. Cancer Gene Ther (1995) 2:19-32.
47. Hwang ES, Naeger LK, DiMaio D: Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene. Oncogene (1996) 12:795-803.
48. Gissmann L, Osen W, Muller M, Jochmus I: Therapeutic vaccines for human papillomaviruses. Intervirology (2001) 44:167-175.
49. Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H, Evans AS, Mason M: Clinical studies of human papilloma vaccines in cervical cancer. Adv Exp Med Biol (2001) 495:419-427.
50. Hietanen S, Lain S, Krausz E, Blattner C, Lane DP: Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA (2000) 97:8501-8506.
51. Baleja JD, Liu Y, Nicklaus MC, Voigt JH, Liu ZG, Chen JJ, Androphy E: Design of papillomavirus inhibitors based on 3-D structures of E6-interacting proteins. 224th ACS National Meeting, Boston, MA, USA, August 18-22 (2002):MEDI-020.
52. Be X, Hong Y, Wei J, Androphy EJ, Chen JJ, Baleja JD: Solution structure determination and mutational analysis of the papillomavirus E6 interacting peptide of E6AP. Biochemistry (2001) 40:1293-1299.
53. Hajduk PJ, Dinges J, Miknis GF, Merlock M, Middleton T, Kempf DJ, Egan DA, Walter KA, Robins TS, Shuker SB, Holzman TF et al: NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. J Med Chem (1997) 40:3144-3150.
54. Pransky SM, Magit AE, Kearns DB, Kang DR, Duncan NO: Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg (1999) 125:1143-1148.
55. Pransky SM, Brewster DF, Magit AE, Kearns DB: Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg (2000) 126:1239-1243.
56. Van Cutsem E, Snoeck R, Van Ranst M, Fiten P, Opdenakker G, Geboes K, Janssens J, Rutgeerts P, Vantrappen G, De Clercq E et al: Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2phosphonylmethoxpropyl)cytosine. J Med Virol (1995) 45:230-235.
57. Martinelli C, Farese A, Mistro AD, Giorgini S, Ruffino I: Resolution of recurrent perianal condylomata acuminata by topical cidovir in patients with HIV infection. J Eur Acad Dermatol Venereol (2001) 15:568-569.
58. Snoeck R, Noel JC, Muller C, De Clercq E, Bossens M: Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J Med Virol (2000) 60:205-209.
59. Andrei G, Snoeck R, Schols D, De Clercq E: Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res (2001) 12:397-408.
60. Johnson JA, Gangemi JD: Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Antimicrob Agents Chemother (1999) 43:1198-1205.
61. Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E: Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice. Oncol Res (1998) 10:533-539.
62. Richwald GA: Imiquimod. Drugs of Today (1999) 35:497-511.
63. Syed TA, Hadi SM, Qureshi ZA, Ali SM, Kwah MS: Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study. J Infect (2000) 41:148-151.
64. Trofatter KF Jr: Imiquimod in clinical practice. Eur J Dermatol (1998) 8:17-19.
65. Colonno RJ, Genovesi EV, Medina I, Lamb L, Durham SK, Huang ML, Corey L, Littlejohn M, Locarnini S, Tennant BC, Rose B et al: Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis (2001) 184:1236-1245.
66. Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, Hsu HM, Chen HL, Hsu HY, Chen DS: Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. J Am Med Assoc (2000) 284:3040-3042.
67. Chang MH: Hepatitis B vaccination and control of hepatitis B-related liver disease. J Pediatr Gastroenterol Nutr (2000) 31:112-117.
68. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med (1997) 336:1855-1859.
69. Cheng YC: L-Nucleoside analogues against cancer-causing viruses have potential in the prevention, delayed onset and treatment of viral associated cancers. Antivir Chem Chemother (2001) 12:5-11.
70. Klein G, Powers A, Croce C: Association of SV40 with human tumors. Oncogene (2002) 21:1141-1149.
71. Ferber D: Virology: Monkey virus link to cancer grows stronger. Science (2002) 296:1012-1015.
72. Khalili K: Human neurotrophic JC virus and its association with brain tumors. Dis Markets (2001) 17:143-147.
73. Shah KV: Polyoma viruses (JC virus, BK virus, and simian virus 40) and human cancer. In: Infectious Causes of Cancer. Goedert JJ (Ed), Humama Press Inc, Totowa, NJ, USA (2000):461-474.
74. Tornatore C: JCV and BKV: Mechanisms of viral transformation. In: Monographs in Virology. Doerr HW (Ed), Karger AG, Basel, Switzerland (2001) 23:1-27.
75. Greaves MF, Alexander FE: An infectious etiology for common acute lymphoblastic leukemia in childhood? Leukemia (1993) 7:349-360.
76. Graves MF: Aetiology of acute leukaemia. Lancet (1997) 349:344-349.
77. Greaves MF: Commentary: Birth order and risk of childhood acute lymphoblastic leukaemia (ALL). Int J Epidemiol (2001) 30:1438-1439.
78. Zur Hausen H: Proliferation-inducing viruses in non-permissive systems as possible causes of humanc cancers. Lancet (2001) 357:381-384.
79. New England Medical Center Hospitals Inc (Androphy EJ, Baleja JD, Chen JJ): Structure-based rational design of compounds to inhibit papillomavirus infection. US-09917616 (1999).
80. Boehringer Ingelheim (Canada) Ltd (Yoakim C, Hache B, Ogilvie WW, O'Meara J, White P, Goudreau N): Preparation of spiroheterocycles for therapeutic use as papilloma virus inhibitors. US-00250082 (2002).